Abstracts tagged "Biomarkers"

Abstract Number: 0120 • ACR Convergence 2022
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Carla J. Guthridge¹, Catriona Wagner², Sohail Khan³, Michael Peercy⁴, Bobby Saunkeah⁴, Joel Guthridge¹ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Cherokee Nation, Tahlequah, OK, ⁴Chickasaw Nation, Ada, OK
Background/Purpose: EBV infection is associated with autoantibody development in the preclinical period of rheumatic diseases, such as SLE and RA. Furthermore, EBV reactivation, characterized by…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 0602 • ACR Convergence 2022
Cellworks Biosimulation Model (CBM) for Rheumatoid Arthritis (RA), Accurately Captures Patient’s Disease Activity at the Molecular Level Using Their Omics Data and Can Bring Personalization to Treatment Selection in RA
Himanshu Grover¹, Ansu Kumar¹, Anushua Chakraborty¹, Susheel George Chandy¹, Vivek Patil¹, Swati Khandelwal¹, Vishwas Joseph¹, Deepak Anil Lala¹, Prashant Ramachandran Nair¹, Karthik Sundara Raju¹, Kunal Ghosh Roy¹, Shahabuddin Usmani¹, Aftab Alam¹, Swaminathan Rajagopalan¹, Yatin Mundkur¹ and Andrew Concoff², ¹Cellworks Group Inc., South San Francisco, CA, ²United Rheumatology, Hauppauge, NY
Background/Purpose: Patients with RA demonstrate varied individual responses to the many treatment options available. In the absence of accurate, precision prediction of medication response, current…
Abstract Number: 0836 • ACR Convergence 2022
Bone Turnover and Physical Activity Before and After Anterior Cruciate Ligament Reconstruction
Elizabeth Wellsandt¹, David Werner¹, Mikayla McKee², Matthew Tao², Kaleb Michaud¹ and Yvonne Golightly¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Individuals after anterior cruciate ligament reconstruction (ACLR) have 8 times higher odds of developing knee osteoarthritis (OA) within 10 years compared to those with…
Abstract Number: 1116 • ACR Convergence 2022
Peripheral Blood DNA Methylation-based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biospecimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project
Chris Dunn¹, Cassandra Sturdy², Cassandra Velasco³, Leoni Schlupp², Emmaline Prinz², Vladislav Izda⁴, Liubov Arbeeva⁵, Yvonne Golightly⁶, Amanda Nelson⁷ and Matlock Jeffries², ¹University of Oklahoma Health Sciences Center, Edmond, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, New York, NY, ⁵University of North Carolina Chapel Hill, Chapel Hill, NC, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes, for which there exist no widely-available biomarkers. We…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…
Abstract Number: 1537 • ACR Convergence 2022
Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis
Line Iversen¹, Ole Østergaard², Tina Friis³, susanne Ullman⁴, Søren Jacobsen⁵ and Jesper Olsen², ¹Department of Dermatology, Odense University Hospital., Odense, Denmark, ²Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, ³Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark
Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from…
Abstract Number: 1748 • ACR Convergence 2022
Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
Michael Tang¹, Addison Pacheco², Zoya Qaiyum³, Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Unresolved, chronic inflammation is a key feature of Ankylosing Spondylitis (AS) yet the immunological events perpetuating remain unclear. The strongest genetic association with AS…
Abstract Number: 1968 • ACR Convergence 2022
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Nora Petrovská², Petra Hánová¹, Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…
Abstract Number: 2160 • ACR Convergence 2022
The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
Henriette Didriksen¹, Øyvind Molberg², Adi Mehta³, Suzana Jordan⁴, Håvard Fretheim³, Einar Gude³, Thor Ueland³, Cathrine Brunborg³, Vyacheslav Palchevskiy⁵, Torhild Garen³, Øyvind Midtvedt³, Arne Andreassen³, Fridtjof Lund-Johansen³, Oliver Distler⁴, John Belperio⁵ and Anna-Maria Hoffmann-Vold³, ¹Oslo University Hospital, Moss, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
Abstract Number: 0123 • ACR Convergence 2022
Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases
Sara Remuzgo-Martinez¹, Belén Atienza-Mateo¹, Veronica Pulito-Cueto¹, Fernanda Genre¹, Víctor M. Mora-Cuesta¹, David Iturbe-Fernández¹, Virgi Portilla¹, María Sebastián Mora-Gil¹, J Gonzalo Ocejo-Vinyals², Oreste Gualillo³, Alfonso Corrales¹, Santos Castañeda⁴, Raquel Lopez Mejias⁵, José M. Cifrián¹ and Miguel Ángel González-Gay⁶, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) may occur in patients with a rheumatic autoimmune disease (AD), increasing their morbidity and mortality [1]. In this regard, the…
Abstract Number: 0362 • ACR Convergence 2022
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis
Hermine I. Brunner¹, Catharina Lindholm², Ellen Cody¹, Prasad Devarajan¹, Bin Huang¹, Dominic Sinibaldi³, Madhu Ramaswamy³, Jacob Knagenhjelm⁴, Tingting Qiu¹, Frederick Jones⁵, Philip Brohawn³, Raj Tummala³ and Wendy White³, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²AstraZeneca, Gothenburg, Sweden, ³AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Gateborg, Sweden, ⁵AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN confers poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We previously showed that…
Abstract Number: 0612 • ACR Convergence 2022
Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response
Siddharth Jain¹, Bidya Laishangtham¹, Aastha Khullar¹, Biman Saikia¹ and Varun Dhir², ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: It is still unclear whether Natural Killer (NK) and Natural Killer T (NKT) cells play a pathogenic or protective role in Rheumatoid Arthritis (RA).…
Abstract Number: 0870 • ACR Convergence 2022
Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
Sevda Gharehbaghi¹, Emily Moise¹, Priya Brito², Lori Ponder³, Omer Inan¹ and Sampath Prahalad⁴, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) refers to all forms of autoimmune arthritis in children with undetermined etiology, and thus it is the most prevalent chronic…
Abstract Number: 1127 • ACR Convergence 2022
Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
Chary Lopez-Pedrera¹, Rafaela Ortega-Castro¹, Tomás Cerdó², Pilar Font¹, María Martinez-Monllor³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², María Carmen Ábalos-Aguilera³, Nuria Barbarroja¹, Eduardo Collantes¹, María Ángeles Aguirre-Zamorano⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain
Background/Purpose: Systemic sclerosis (SSc) is an heterogeneous autoimmune disease. There is an unmet need of biomarkers for diagnosis, progression and therapeutic response.This study aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].